Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000286629 encodes a long non-coding RNA that is transcribed in the antisense orientation relative to the ERN1 gene. As with other natural antisense transcripts, its primary known role is the regulation of gene expression, typically through interactions with chromatin, transcript stability, and possibly epigenetic modification. Antisense RNAs can influence their corresponding sense gene (here, ERN1) by modifying transcription rates, altering transcript processing, changing RNA stability, or affecting chromatin structure, often via changes in histone modification or DNA methylation. No direct evidence supports its function as a therapeutic target, disease biomarker, or drug target, and there are no known drugs interacting with this transcript. Sequence and function information are very limited; it is not a canonical therapeutic target, receptor, enzyme, or protein-coding gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel antisense transcript to ERN1.